Latest News about ASND
Recent news which mentions ASND
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Today 17:02 EDT
From Benzinga
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Today 9:09 EDT
From Benzinga
From Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
August 13, 2024
From Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
May 15, 2024
From Benzinga
From Benzinga
Tickers
ASND
From InvestorPlace
From Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
April 03, 2024
From Benzinga
From Benzinga
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
March 03, 2024
From Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
February 23, 2024
From Benzinga
From Benzinga
Earnings Scheduled For February 7, 2024
February 07, 2024
From Benzinga
From Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
December 19, 2023
Tickers
ASND
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.